Literature DB >> 19481198

Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease.

Olivier Berton1, Céline Guigoni, Qin Li, Bernard H Bioulac, Incarnation Aubert, Christian E Gross, Ralph J Dileone, Eric J Nestler, Erwan Bezard.   

Abstract

BACKGROUND: Involuntary movements, or dyskinesia, represent a debilitating complication of dopamine replacement therapy for Parkinson disease (PD). The transcription factor DeltaFosB accumulates in the denervated striatum and dimerizes primarily with JunD upon repeated L-3,4-dihydroxyphenylalanine (L-DOPA) administration. Previous studies in rodents have shown that striatal DeltaFosB levels accurately predict dyskinesia severity and indicate that this transcription factor may play a causal role in the dyskinesia sensitization process.
METHODS: We asked whether the correlation previously established in rodents extends to the best nonhuman primate model of PD, the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned macaque. We used western blotting and quantitative polymerase chain reaction (PCR) to compare DeltaFosB protein and messenger RNA (mRNA) levels across two subpopulations of macaques with differential dyskinesia severity. Second, we tested the causal implication of DeltaFosB in this primate model. Serotype 2 adeno-associated virus (AAV2) vectors were used to overexpress, within the motor striatum, either DeltaFosB or DeltaJunD, a truncated variant of JunD lacking a transactivation domain and therefore acting as a dominant negative inhibitor of DeltaFosB.
RESULTS: A linear relationship was observed between endogenous striatal levels of DeltaFosB and the severity of dyskinesia in Parkinsonian macaques treated with L-DOPA. Viral overexpression of DeltaFosB did not alter dyskinesia severity in animals previously rendered dyskinetic, whereas the overexpression of DeltaJunD dramatically dropped the severity of this side effect of L-DOPA without altering the antiparkinsonian activity of the treatment.
CONCLUSIONS: These results establish a mechanism of dyskinesia induction and maintenance by L-DOPA and validate a strategy, with strong translational potential, to deprime the L-DOPA-treated brain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19481198      PMCID: PMC2825375          DOI: 10.1016/j.biopsych.2009.04.005

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  40 in total

1.  An essential role for DeltaFosB in the nucleus accumbens in morphine action.

Authors:  Venetia Zachariou; Carlos A Bolanos; Dana E Selley; David Theobald; Michael P Cassidy; Max B Kelz; Tamara Shaw-Lutchman; Olivier Berton; Laura J Sim-Selley; Ralph J Dileone; Arvind Kumar; Eric J Nestler
Journal:  Nat Neurosci       Date:  2006-01-15       Impact factor: 24.884

2.  Effect of antisense FosB and CREB on the expression of prodynorphin gene in rats with levodopa-induced dyskinesias.

Authors:  Zhibin Chen; Qiang Guan; Xuebing Cao; Yan Xu; Lan Wang; Shenggang Sun
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

3.  Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease.

Authors:  J E Westin; M Andersson; M Lundblad; M A Cenci
Journal:  Eur J Neurosci       Date:  2001-10       Impact factor: 3.386

4.  ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.

Authors:  Nancy Pavón; Ana B Martín; Ainhoa Mendialdua; Rosario Moratalla
Journal:  Biol Psychiatry       Date:  2005-09-01       Impact factor: 13.382

5.  Expression pattern of JunD after acute or chronic L-DOPA treatment: comparison with deltaFosB.

Authors:  B Valastro; M Andersson; H S Lindgren; M A Cenci
Journal:  Neuroscience       Date:  2006-10-19       Impact factor: 3.590

6.  Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease.

Authors:  P K Tekumalla; F Calon; Z Rahman; S Birdi; A H Rajput; O Hornykiewicz; T Di Paolo; P J Bédard; E J Nestler
Journal:  Biol Psychiatry       Date:  2001-11-15       Impact factor: 13.382

7.  Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey.

Authors:  T Boraud; E Bezard; B Bioulac; C E Gross
Journal:  Brain       Date:  2001-03       Impact factor: 13.501

8.  Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

Authors:  E Bezard; S Dovero; C Prunier; P Ravenscroft; S Chalon; D Guilloteau; A R Crossman; B Bioulac; J M Brotchie; C E Gross
Journal:  J Neurosci       Date:  2001-09-01       Impact factor: 6.167

9.  High-frequency stimulation of the subthalamic nucleus potentiates L-DOPA-induced neurochemical changes in the striatum in a rat model of Parkinson's disease.

Authors:  Abid Oueslati; Véronique Sgambato-Faure; Christophe Melon; Philippe Kachidian; Paolo Gubellini; Mohammed Amri; Lydia Kerkerian-Le Goff; Pascal Salin
Journal:  J Neurosci       Date:  2007-02-28       Impact factor: 6.167

10.  Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease.

Authors:  M Andersson; A Hilbertson; M A Cenci
Journal:  Neurobiol Dis       Date:  1999-12       Impact factor: 5.996

View more
  30 in total

1.  Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements.

Authors:  Xuebing Cao; Toru Yasuda; Subramaniam Uthayathas; Ray L Watts; M Maral Mouradian; Hideki Mochizuki; Stella M Papa
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

2.  Discovery of phenanthridine analogues as novel chemical probes disrupting the binding of DNA to ΔFosB homodimers and ΔFosB/JunD heterodimers.

Authors:  Yi Li; Zhiqing Liu; Galina Aglyamova; Jianping Chen; Haiying Chen; Mukund Bhandari; Mark A White; Gabrielle Rudenko; Jia Zhou
Journal:  Bioorg Med Chem Lett       Date:  2020-06-06       Impact factor: 2.823

3.  Overexpression of GRK6 rescues L-DOPA-induced signaling abnormalities in the dopamine-depleted striatum of hemiparkinsonian rats.

Authors:  M Rafiuddin Ahmed; Evgeny Bychkov; Seunghyi Kook; Lilia Zurkovsky; Kevin N Dalby; Eugenia V Gurevich
Journal:  Exp Neurol       Date:  2015-02-14       Impact factor: 5.330

4.  Modeling Parkinson's disease in primates: The MPTP model.

Authors:  Gregory Porras; Qin Li; Erwan Bezard
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

Review 5.  G protein-coupled receptor kinases as regulators of dopamine receptor functions.

Authors:  Eugenia V Gurevich; Raul R Gainetdinov; Vsevolod V Gurevich
Journal:  Pharmacol Res       Date:  2016-05-10       Impact factor: 7.658

6.  Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia.

Authors:  Stefania Fasano; Erwan Bezard; Angela D'Antoni; Veronica Francardo; Marzia Indrigo; Li Qin; Sandra Doveró; Milica Cerovic; M Angela Cenci; Riccardo Brambilla
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-29       Impact factor: 11.205

7.  Pharmacological recruitment of the GABAergic tail of the ventral tegmental area by acute drug exposure.

Authors:  Jennifer Kaufling; Elisabeth Waltisperger; Romain Bourdy; Antoine Valera; Pierre Veinante; Marie-José Freund-Mercier; Michel Barrot
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

8.  A Subpopulation of Striatal Neurons Mediates Levodopa-Induced Dyskinesia.

Authors:  Allison E Girasole; Matthew Y Lum; Diane Nathaniel; Chloe J Bair-Marshall; Casey J Guenthner; Liqun Luo; Anatol C Kreitzer; Alexandra B Nelson
Journal:  Neuron       Date:  2018-02-01       Impact factor: 17.173

9.  Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia.

Authors:  Emanuela Santini; Veronique Sgambato-Faure; Qin Li; Marc Savasta; Sandra Dovero; Gilberto Fisone; Erwan Bezard
Journal:  PLoS One       Date:  2010-08-23       Impact factor: 3.240

10.  A Pharmacogenetic Discovery: Cystamine Protects Against Haloperidol-Induced Toxicity and Ischemic Brain Injury.

Authors:  Haili Zhang; Ming Zheng; Manhong Wu; Dan Xu; Toshihiko Nishimura; Yuki Nishimura; Rona Giffard; Xiaoxing Xiong; Li Jun Xu; J David Clark; Peyman Sahbaie; David L Dill; Gary Peltz
Journal:  Genetics       Date:  2016-03-18       Impact factor: 4.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.